Evidence map›Paper›PMID 32726539›Full record

Trial reportThe New England journal of medicine2020

Ibrutinib for Chronic Lymphocytic Leukemia with

Inhye E Ahn, Xin Tian, Adrian Wiestner

Open access · bronzeAbstract readClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The New England journal of medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 113 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Inhye E AhnNational Heart, Lung, and Blood Institute, Bethesda, MD wiestnea@nhlbi.nih.gov.ORCID 0000-0003-3717-287X
Xin TianNational Heart, Lung, and Blood Institute, Bethesda, MD wiestnea@nhlbi.nih.gov.
Adrian WiestnerNational Heart, Lung, and Blood Institute, Bethesda, MD wiestnea@nhlbi.nih.gov.
National Heart Lung and Blood Institute · US

Funding

Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapyZIAHL002346 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI WIESTNER, ADRIAN U · 2009 to 2025
$29.8M
American Society of Hematology Scholar AwardIntramural NIH HHS ZIA HL002346NIH Clinical Center NAPharmacyclics N/A
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdenineAdultAgedAged, 80 and overAntineoplastic AgentsDisease ProgressionFemaleFollow-Up StudiesHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedMutationPiperidinesProtein Kinase InhibitorsPyrazolesAdenineAntineoplastic AgentsibrutinibPiperidinesProtein Kinase InhibitorsPyrazolesPyrimidinesTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID32726539
PMCPMC7456330
OpenAlexW3045542125

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.